NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

The booming uptake of anti-obesity drugs in India is further underscored by rising momentum of Eli Lilly's Mounjaro, which ...

Asking people with type 2 diabetes their language and care preferences is vital to optimise outcomes globally, says Heather Koga As the US writer Ingrid Bengis said, “Words are a form of action, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...

Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...

Review the current Eli Lilly and Co (LLY:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if LLY is the best investment for you.

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...